Picture of Guangdong Investment logo

270 — Guangdong Investment News Story

0.000.00%
hk flag iconLast trade - 00:00
UtilitiesAdventurousLarge CapSuper Stock

Guangdong Investment 9M revenue rises on water resources strength

Guangdong Investment 9M revenue rises on water resources strength


Overview

  • Hong Kong water resources firm's nine-month revenue from continuing ops rose 10% yr/yr, driven by water resources

  • Net income attributable to owners from continuing ops increased 7.3% yr/yr

  • Company completed special dividend distribution of GD Land shares in January


Outlook

  • Company did not provide specific financial guidance for future quarters or full-year forecasts in the press release


Result Drivers

  • WATER RESOURCES GROWTH – Higher water-resources revenue drove the Group's 10.0% revenue increase; other water projects rose 16.5% to HK$6.54 bln

  • FINANCE COST SAVINGS – Net finance costs fell to HK$201 mln from HK$263 mln, supporting profit before tax growth

  • ENERGY COST PRESSURE – Higher coal prices cut GDH Energy's profit before tax 14.1% despite a 10.5% increase in electricity sales


Company press release: Full Story


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue from Cont Ops

HK$15.71 bln

9M Net Income Attributable from Cont Ops

HK$4.36 bln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the water & related utilities peer group is "buy."

  • Wall Street's median 12-month price target for Guangdong Investment Ltd is HK$9.50, about 9.6% above its October 27 closing price of HK$8.67

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago


Reuters Recommended Reads

  • Oct 26 - Guangdong Land nine-month revenue drops 20% on lower property sales

  • Oct 26 - Singapore's IFAST Q3 revenue rises on ePension growth

  • Oct 27 - China's Hengrui Pharma nine-month profit rises on out-licensing gains


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Guangdong Investment

See all news